The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Core Laboratories' revenues will grow 11.8% and EPS will improve 28.9%.
The average estimate for revenue is $252.5 million. On the bottom line, the average EPS estimate is $1.16.
Last quarter, Core Laboratories chalked up revenue of $234.2 million. GAAP reported sales were 13% higher than the prior-year quarter's $206.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.06. GAAP EPS of $1.13 for Q1 were 20% higher than the prior-year quarter's $0.94 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 36.3%, 240 basis points better than the prior-year quarter. Operating margin was 29.6%, 290 basis points better than the prior-year quarter. Net margin was 23.0%, 60 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $1.03 billion. The average EPS estimate is $4.81.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 544 members out of 555 rating the stock outperform, and 11 members rating it underperform. Among 118 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 117 give Core Laboratories a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Core Laboratories is hold, with an average price target of $121.00.
- Add Core Laboratories to My Watchlist.